NCT04907331 (HeVacc) is a Phase 2 clinical trial of Vaxzevria in SARS-CoV2 Infection, sponsored by Medical University Innsbruck.

Who is sponsoring NCT04907331?

NCT04907331 is sponsored by Medical University Innsbruck.

What drugs are being tested in NCT04907331?

Interventions in NCT04907331: Vaxzevria, Comirnaty.

What condition does NCT04907331 study?

NCT04907331 studies SARS-CoV2 Infection.

Is NCT04907331 still recruiting?

NCT04907331 is currently status unknown. Last updated 10 September 2021.

Last reviewed 2021-09-10 · How we verify

NCT04907331: HeVacc

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2

Status unknown Phase 2 Last updated 10 September 2021

What this trial tests

Phase 2 trial testing Vaxzevria in SARS-CoV2 Infection in 3,000 participants. Status unknown.

Timeline

10 May 2021

Primary endpoint
30 November 2021

30 December 2021

Quick facts

Lead sponsor	Medical University Innsbruck
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	3,000
Start date	10 May 2021
Primary completion	30 November 2021
Estimated completion	30 December 2021
Sites	1 location across Austria

Drugs / interventions tested

Vaxzevria — full drug profile →
Comirnaty (BNT162b2 (tozinameran)) — full drug profile →

Conditions studied

SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →

Sponsor

Medical University Innsbruck

Who can join

Adults 18 to 65, any sex, with SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will analyze the safety and efficacy of the heterologous vaccination with Vaxzevria followed by Comirnaty. As a control individuals will be vaccinated with Comirnaty or Vaxzevria twice. Each arm will involve 1000 individuals. Endpoints will be the level of antibody and T cell response as well as frequency of vaccine failures.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

mRNA vaccines for infectious diseases: principles, delivery and clinical translation.
Chaudhary N, Weissman D, Whitehead KA. · · 2021 · cited 1014× · PMID 34433919 · DOI 10.1038/s41573-021-00283-5
Advances in COVID-19 mRNA vaccine development.
Fang E, Liu X, Li M, Zhang Z, et al · · 2022 · cited 368× · PMID 35322018 · DOI 10.1038/s41392-022-00950-y
Cancer vaccines: Building a bridge over troubled waters.
Sellars MC, Wu CJ, Fritsch EF. · · 2022 · cited 247× · PMID 35835100 · DOI 10.1016/j.cell.2022.06.035
Efficacy and safety of COVID-19 vaccines.
Graña C, Ghosn L, Evrenoglou T, Jarde A, et al · · 2022 · cited 227× · PMID 36473651 · DOI 10.1002/14651858.cd015477
To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination.
Chiu NC, Chi H, Tu YK, Huang YN, et al · · 2021 · cited 93× · PMID 34415818 · DOI 10.1080/14760584.2021.1971522
mRNA vaccines: the most recent clinical applications of synthetic mRNA.
Kwon S, Kwon M, Im S, Lee K, et al · · 2022 · cited 50× · PMID 35426547 · DOI 10.1007/s12272-022-01381-7
Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial.
Bánki Z, Mateus J, Rössler A, Schäfer H, et al · · 2022 · cited 32× · PMID 35617826 · DOI 10.1016/j.ebiom.2022.104073
Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19.
Agrati C, Capone S, Castilletti C, Cimini E, et al · · 2021 · cited 17× · PMID 34737309 · DOI 10.1038/s41541-021-00394-5

Verify or expand the search:

Other recruiting trials for SARS-CoV2 Infection

Currently open trials in the same condition.

NCT05852873 — PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway · Phase 3 · active not recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04830852 — Pediatric COVID Outcomes Study (PECOS) · active not recruiting
NCT04844242 — MISC COVID-19 Study in Pediatric Population · recruiting

Other Medical University Innsbruck trials

Trials by the same sponsor.

NCT07408726 — Monoaxial vs. Polyaxial Percutaneous Hybrid Stabilization · NA · not yet recruiting
NCT07101107 — Socio-cognitive and Biological Responses to Maltreatment · not yet recruiting
NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07434648 — Comparison of Mastectomy Expander Trial · NA · not yet recruiting
NCT07391683 — Telemedically Assisted Optimization for Heart Failure Patients Before Cardiac Surgery to Improve Perioperative Outcome · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04907331 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University Innsbruck
Last refreshed: 10 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04907331.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing